Cytokine regulation of tight junctions  by Capaldo, Christopher T. & Nusrat, Asma
Biochimica et Biophysica Acta 1788 (2009) 864–871
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemReview
Cytokine regulation of tight junctions
Christopher T. Capaldo, Asma Nusrat ⁎
Epithelial Pathobiology Research Unit, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA⁎ Corresponding author.
E-mail address: anusrat@emory.edu (A. Nusrat).
0005-2736/$ – see front matter © 2008 Elsevier B.V. A
doi:10.1016/j.bbamem.2008.08.027a b s t r a c ta r t i c l e i n f oArticle history: Epithelial and endothelial
Received 12 March 2008
Received in revised form 26 August 2008
Accepted 27 August 2008
Available online 8 October 2008
Keywords:
Tight junction
Cytokine
IFN-gamma
TNF-alpha
Claudin
Interleukin
ZO-1
Paracellular permiabilitytight junctions act as a rate-limiting barrier between an organism and its
environment. Continuing studies have highlighted the regulation of the tight junction barrier by cytokines.
Elucidation of this interplay is vital for both the understanding of physiological tight junction regulation and
the etiology of pathological conditions. This review will focus on recent advances in our understanding of the
molecular mechanisms of tight junctions modulation by cytokines.
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Cytokinemediated changes in paracellular permeability contribute
to a multitude of pathologic conditions including inﬂammatory bowel
disease (IBD), airway inﬂammation in asthma [1] and cystic ﬁbrosis
[2], and diseases that perturb the blood-brain barrier (BBB) [3].
Cytokines also regulate diverse physiological, developmental, and
non-inﬂammatory processes such as spermatocyte transmigration
across the blood testis barrier [4] and mammary epithelial cell
differentiation [5]. Epithelial and endothelial barrier function isll rights reserved.maintained by intercellular Tight Junctions (TJs), multi-protein
complexes that seal the space between adjacent cells. It is therefore
easy to envision that cytokine mediated perturbation of TJ function
results in enhanced paracellular permeability and increased exposure
of tissues to luminal antigens in organ systems such as the
gastrointestinal and respiratory tracts. While the molecular mechan-
isms that regulate these processes are incompletely understood, our
knowledge is rapidly expanding through the use of reductionistic
model cell culture systems of inﬂammation and epithelial/endothelial
barrier function. This review will focus on recent ﬁndings that clarify
the signaling processes underlying cytokine modulation of epithelial
and endothelial barrier function.
As a case in point, chronic recurring inﬂammation of the intestinal
mucosa and loss of the epithelial barrier is observed in IBD. One of the
major clinical manifestations of IBD, which encompasses both Crohn's
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While the pathophysiology of these disorders is complex, an
important underlying basis of these diseases is the existence of an
abnormal “leaky” epithelial barrier that results in aberrant tissue
exposure to luminal antigens and pathogens. Increased epithelial
paracellular permeability has been documented in epithelium from
acutely inﬂamed and chronically damaged intestinal mucosa. Further-
more, enhanced epithelial barrier dysfunction has been observed in
ﬁrst-degree relatives of patients with Crohn's disease, which suggests
that a genetic component contributes to loss of barrier function and
the pathophysiology of this disorder [6,7]. In animal models of IBD
such as the SAMP/Yit model, increased epithelial paracellular
permeability precedes chronic intestinal mucosal inﬂammation [8].
Additionally, in animal models such as the mdr1a−/−mouse, altered
epithelial barrier function has been associated with the subsequent
development of colitis [9]. These observations further support the
critical role of epithelial TJ protein complexes in maintaining mucosal
tissue homeostasis. A broad array of cytokines perturb epithelial and
endothelial barrier function by inﬂuencing the structure and function
of the TJ. Table 1 contains a list of cytokines that inﬂuence epithelial/
endothelial permeability to ions (⁎), and/or small molecules (#), and
highlights postulated cytokine mechanisms of action. Experimentally,
TJ barrier function is assessed by measurement of transepithelial (or
endothelial) electrical resistance (TER), and the ability of TJs to restrict
the passage of small molecules such as inulin, mannitol, or dextran
through the paracellular space. Elucidating themolecularmechanismsTable 1
Paracellular permeability changes due to cytokine treatment
Cytokine Permeability Cells Mechanism
IFN-γ Increased⁎ # T84 Actin reorganization, ↓ ZO-1 [21]
Decrease⁎ # Calu-3 Unkn [14]
– T84 Myosin II-dependent vacuolarization,
MLC/Rho/ROCK [25]
Increase⁎ # T84 ↔ JAM-A, occludin, claudins1/4 [22]
Increase⁎ # T84 Unkn [17,86]
Increase⁎ MVECs Actin structure [20]
Increase⁎ # Cholangiocytes Unkn [60]
Increase⁎ HUVECs ↓ Occludin, ↓ E-Cadherin [27]
TNFα Increase# HUVECs ↓ Occludin,↔ claudin 5
and JAM-A [40]
Increase# BPAEC Actin restructuring [107]
Increase⁎ Caco-2 Unkn [108]
Increase⁎ Caco-2 NF-κB, MLCK [38]
Increase⁎ # Caco-2 NF-κB, ↓ ZO-1 [36]
Decrease⁎ UEC Unkn [32]
Decrease⁎ LLC-PK1 Unkn [31]
Increase⁎ # HT29/B6 Lowered TJ complexity [99]
Increase⁎ # MVEC Actin restructuring [20]
Increase⁎ # LLC-PK1 Apoptosis [34]
Increase⁎ # LLC-PK1 Unkn [33]
Increase⁎ # cholangiocytes Unkn [60]
IFN-γ+TNF-α – HEC Unkn [6],↔ JAM-A [40]
Increase⁎ PAC Unkn [2]
Increase⁎ # T84 Unkn [43],↓ Claudin 2,3↔
Claudin 4 [41]
Increase⁎ T84 Altered lipid composition [46]
Increase⁎ # T84/Caco-2 MLC/MLCK [42]
Increase⁎ # Caco-2 MLCK [44]
Increased# MVECs ↔ Claudin 5 [45]
IFN-γ+LIGHT Increase⁎ Caco-2 MLCK, caveolar endocytosis [47]
IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha; LIGHT, lymphotoxin-like
inducible protein that competes with glycoprotein D for herpes virus entry on T cells;
⁎, transepithelial resistance; #, small molecule ﬂux; HUVECs, human umbilical vascular
endothelial cells; BPAEC, bovine pulmonary artery endothelial cell; Caco-2, human
colonic adenocarcinoma; UEC, uterine epithelial cells; T84, human colonic epithelial
cells; Calu-3, human lung epithelial cells; MVEC, microvascular endothelial cells; PAC,
primary airway cells; LLC-PK1, porcine renal epithelial cells;↔, change in localization;
↓, decrease protein or mRNA levels; ↑, increased protein or mRNA levels; Unkn,
unknown; JAM-A, junctional adhesion molecule A; NF-κB, nuclear factor-kappa B;
MLCK, myosin light chain kinase; ZO-1, zonula occludins 1; ROCK, Rho associated kinase.behind the interplay between cytokines and epithelial permeability is
vital for understanding the causes and complications of inﬂammatory
disorders such as IBD.
2. IFN-γ
Interferon gamma (IFN-γ) is a Th1 pro-inﬂammatory cytokine
found at elevated levels in the intestinal mucosa of IBD patients [10–12].
In addition to its immunomodulatory role during inﬂammation,
IFN-γ acts to modify epithelial and endothelial barrier function. In
model cell culture systems of inﬂammation, direct treatment with
IFN-γ increases the paracellular permeability of endothelial and
epithelial monolayers (see Table 1). However, in airway epithelial
cells, IFN-γ exposure has anti-inﬂammatory properties and pro-
motes epithelial barrier function; indicative of pleiotropic effects
[13,14]. The reason for this discrepancy is unclear, although it
should be noted that airway inﬂammatory episodes are considered
primarily a Th2 mediated response [15]. The mechanisms through
which IFN-γ inﬂuences epithelial/endothelial permeability are
beginning to be understood at the molecular level. First observed
in endothelial cell cultures by Stolpen et al., treatment with
recombinant IFN-γ causes actin rearrangement into stress ﬁbers
[16]. More subtle changes in actin structure were observed in T84
epithelial cells which, with IFN-γ treatment, show contraction of
cortical actin co-incident with epithelial barrier dysfunction [17]. TJ
transmembrane proteins are linked by scaffolding proteins to the
actin–myosin cytoskeleton, and disruption of acto-myosin structures
has long been understood to modulate paracellular permeability
[18,19]. These observations are consistent with the hypothesis that
actin–myosin restructuring plays a central role in cytokine mediated
permeability changes.
Endothelial and epithelial cells respond to IFN-γ by restructuring
actin and by decreasing protein levels or subcellular localization of the
scaffolding protein ZO-1 [20,21]. In T84 epithelial cells, the TJ
transmembrane proteins, claudin, occludin, and junction adhesion
molecule A (JAM-A), are internalized away from cell–cell contact
regions [22,23]. When visualized by immunoﬂuorescence microscopy,
these TJ components become disorganized and discontinuous at the
lateral membrane after IFN-γ treatment [21,22]. This may indicate an
enhancement of constitutive TJ remodeling as opposed to gross TJ
dissolution. Indeed, internalization of TJ proteins in response to IFN-γ
proceeds by macropinocytosis into early recycling endosomes and
requires acto-myosin based contraction [24,25]. It is therefore feasible
that IFN-γ increases acto-myosin contractility, promoting endocytosis
of TJ structures. Endothelial cells treated with IFN-beta 1a and 1b
blocked IFN-γ induced endocytosis of cadherin based junctions and
maintained barrier integrity, suggesting a conserved mechanism
between endothelial and epithelial responses [26]. Interestingly,
mucosal biopsies from patients with actively inﬂamed UC show
internalized sub-apical vesicles, similar to those found in T84 cells
treated with IFN-γ, that contain TJ transmembrane proteins. This
suggests that vesicle mediated internalization of TJ proteins is an in-
vivo mechanism involved in permeability changes [24].
Recent studies have explored in greater depth the molecular
mechanisms behind actin contractility, TJ protein endocytosis, and
barrier function. IFN-γ exposure was found to activate the small
GTPase RhoA and increase the expression of Rho associated kinase
(ROCK), which in turn phosphorylates and activates myosin light
chain (MLC) [25]. ROCK can also regulate MLC through inactivation of
MLC phosphatase [27]. RhoA is a powerful regulator of actin
remodeling associated with the formation of stress ﬁbers (reviewed
in [28]). Importantly, these data help to explain two consistently
observed cellular responses to IFN-γ treatment: actin restructuring
and acto-myosin contractility. However, the signaling pathways by
which IFN-γ activates Rho/ROCK and the mechanisms of acto-myosin
induced macropinocytosis remain unclear.
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The pro-inﬂammatory cytokine tumor necrosis factor alpha (TNF-
α), like IFN-γ, is implicated in IBD pathogenesis and is found in
increased levels in the pulmonary sputum of cystic ﬁbrosis patients
[29,30]. Using in-vitro model systems, TNF-α has been shown to
directly impair TJ function in a number of epithelial and endothelial
cell lines (see Table 1). Yet conﬂicting reports exist in several systems
that complicate mechanistic interpretations of TNF-α responses.
These may reﬂect cell type speciﬁc variation, as well as differences in
the length and dose of cytokine treatment [31,32]. TNF-α mediated
increases in permeability were ﬁrst described using the porcine renal
cell line LLC-PK1, which shows an early (b3 h) transient increase in
permeability that quickly returns to normal levels (~5 h) [33]. A
more recent study by this group implicated cell apoptosis, although
the authors speculated that barrier dysfunction was due to actin and
TJ rearrangement as apoptotic cells were extruded from the
monolayer [34]. Through pharmacological inhibition and the over-
expression of dominant negative I kappa B alpha (IκBα) mutants, the
subsequent barrier recovery was shown to be mediated by nuclear
factor-kappa B(NF-κB) [35]. TNF-α-stimulated NF-κB signal trans-
duction has garnered much attention in recent studies. In the
intestinal epithelial cell line Caco-2, TNF-α exerts a delayed effect on
cell permeability. This results in an increase in small molecule ﬂux
within 24 h of treatment, and alters TER by 48 h post-treatment [36].
The authors point to a decrease in ZO-1 protein levels at both these
time points, indicating an additional mechanism may be involved.
The role of NF-κB was investigated by pharmacological inhibition,
which ameliorated barrier defects, and stabilized ZO-1 subcellular
localization and protein levels. A thorough investigation over several
studies revealed that NF-κB acts to increase myosin light chain kinase
(MLCK) transcription during TNF-α treatment [36–38]. Moreover,
this correlated with increases in MLCK protein levels, MLC hyperpho-
sphorylation, and increased paracellular permeability. In endothelial
cells, MLC phosphorylation and RhoA activation are early events after
TNF-α treatment and correlate with increased permeability [39].
Together, these ﬁndings are suggestive of a mechanism involving
enhanced actin contractility similar to IFN-γ. However, in endothelial
cells, pharmacological inhibition of ROCK or MLCK altered the early
morphological changes observed but failed to improve barrier
function [39]. Permeability changes in endothelial cells, which
occur after several days of treatment, do not correlate with RhoA
or MLC activation, but rather with decreased occludin levels andFig. 1.Mechanisms of paracellular permeability modulation by cytokines. The ﬁgure depicts c
barrier dysfunction. (1) In response to cytokine activity, tight junction structure is maintain
“tight” barrier properties are replaced with those with “leaky” properties. (2) Internalization
yet converge on MLC.mislocalization of TJ transmembrane components claudin 5 and JAM-
A. The authors conclude that long-term barrier dysfunction caused by
TNF-α treatment is therefore due to TJ remodeling rather than acto-
myosin contractility. The reason for the discrepancy between
epithelial and endothelial systems is unclear, but may be indicative
of cell-speciﬁc mechanisms for TJ remodeling during acute or chronic
exposure.
4. Combined effects of TNF-α and IFN-γ
Under inﬂammatory conditions, target cells are exposed to a
variety of cytokines. While model cell culture systems exposed to
multiple cytokines may complicate mechanistic interpretation, it
likely reﬂects many endogenous cellular environments. Both epithe-
lial and endothelial cell culture systems exposed to TNF-α and IFN-γ
simultaneously show increased paracellular permeability (see Table
1). Investigations into the molecular pathways involved report
ﬁndings that are largely consistent with studies using either cytokine
alone. These include altered actin structure, displacement or down
regulation of TJ proteins, and activation of acto-myosin contractility
pathways [16,40–42]. Interestingly, cotreatment reveals a synergy
between TNF-α and IFN-γ, with relative increases in barrier dysfunc-
tion and sensitization of airway epithelial cells to IFN-γ [2,43,44].
Combined treatment with TNF-α and IFN-γ results in mislocalization
into the cytoplasm of tight junction proteins such as JAM-A , claudin 4
and claudin 5 [40,41,45]. Indeed, TJ proteins such as occludin and JAM
have decreased membrane raft association in model intestinal
epithelial cells exposed to a combination of TNF-α and IFN-γ [46].
The lymphotoxin-like inducible protein LIGHT, a TNF family member,
also synergizes with IFN-γ to increase paracellular permeability [47].
MLC phosphorylation increases with combined TNF-α and IFN-γ
treatment in Caco-2 epithelial cells [42]. The engagement of the
myosin motor is essential for IFN-γ/TNF-α induced permeability
changes in T84 cells, as myosin inhibition with pharmacological
inhibitors reduces endocytosis in cytokine treated cells [42]. Although
not required for protein internalization in T84 cells, MLCK is
upregulated in Caco-2 cells treated with IFN-γ and TNF-α [25,42].
Consistent with these observations, MLCK transcript was found to be
upregulated by priming cultured cells with IFN-γ prior to TNF-α
exposure [48]. This response, as with TNF-α alone, proceeds in a NF-
κB dependent manner [44]. These data suggest that IFN-γ and TNF-α
signal through independent pathways that converge at MLC phos-
phorylation (see Fig. 1.2). The mechanism of IFN-γ and TNF-α synergyells in amonolayer undergoing stimulation and tight junction remodeling that results in
ed but tight junction protein composition is altered. Tight junction proteins that confer
of TJ structures is due to acto-myosin contractility. The pathways are cytokine speciﬁc
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cultures for TNF-α treatment by upregulating the TNF-α cell surface
receptor [49].
5. Interleukins
Interleukins (IL) are a large family of cytokines, and several have
been studied for effects on paracellular permeability in-vitro. These
include IL-1, 2, 4, 6, 8,10, and 13, all of which have been found to have a
variety of effects on epithelial and endothelial paracellular perme-
ability (Table 2). Interleukin-1 (IL-1) is type 1 pro-inﬂammatory
cytokine that is elevated in the intestinal mucosa of patients with IBD
and in the bronchoalveolar lavage ﬂuid from asthma patients [50,51].
In both epithelial and endothelial in-vitro cell culture systems, IL-1
addition to growth media directly increases paracellular permeability
to ions and small molecules [52,53]. In the model intestinal epithelial
cell line Caco-2, IL-1 treatment decreases occludin protein levels due,
at least in part, to the reduction of occludin mRNA levels [53]. This is
consistent with previous ﬁndings in astrocytes, where IL-1β treatment
suppressed occludin protein levels [54]. While occludin knockout
mice have normal intestinal permeability (as measured by both trans-
epithelial resistance (TER) and mannitol ﬂux) they develop chronic
inﬂammation, gastritis, and bone defects [55–57]. Indeed, exogenous
occludin expression in MDCK cells increased TJ strand complexity and
number, as well as decreasing cell permeability [58]. While the role of
occludin in regulation of TJs is still incompletely understood, these
studies clearly highlight a relationship between aberrant occludin
expression and TJ permeability. IL-2 knockout mice exhibit sponta-
neous UC-like symptoms, yet speciﬁc effects on TJ protein composi-
tion and morphology have not shown direct effects by IL-2 [59,60]. IL-
4 treatment increases permeability in model intestinal epithelial T84
cells as well as in Calu-3 airway epithelial cells, which after 24 h of
treatment demonstrate decreased TER [14,61]. Small molecule ﬂux
across the epithelium increases with extended IL-4 treatment (48 h),
which corresponds with a decrease in the protein levels of ZO-1 andTable 2
Permeability modiﬁcation by interleukins and growth factors
Cytokine Permeability Cells Mechanism
IL-1 Increase⁎ # HUVECs Unkn [52]
Increase⁎ # Caco-2 NF-кB, ↓ occludin [53]
– Astrocytes ↑ Claudin 1, ↓ occludin [54]
Increase⁎ PAE Unkn [2]
IL-4 Increase⁎ # Calu-3 ↓ ZO-1,↔ occludin [14]
Increase⁎ # T84 Unknown [61] ↑claudin 2 [62]
IL-6 Increase# Intestine ↓ ZO-1 [66]
Increase⁎ HUVECs Actin restructuring,↔ ZO-1,
PKC (α or β) [67]
IL-10 Decrease# Liver ↑ ZO-1,↔ claudin 1 [70]
Decrease⁎ # T84 Antagonizes IFN-γ [68]
Decrease⁎ # HUVECs Antagonizes IFN-γ, ↑ occludin [69]
IL-13 Increase⁎ # T84 ↑ Claudin 2 [41]
Increase⁎ # Calu-3 ↓ ZO-1,↔ occludin [14]
TGFβ Increase⁎ UEC Unkn [32]
– hepatocytes ↓ Claudin 1, ↑ claudin 2, SMAD [79]
Decrease⁎ T84 ↑ Claudin 2, ERK, MAPK, SMAD [72,73]
HGF/SF Increase# Cerebrovascula ↓ Occludin, ↓ ZO-1 [81]
Decrease⁎ UEC Unkn [32]
HB-EGF Decrease⁎ MDCK ↓ Claudin 2 [83]
PDGF Increased# MDCK TJ structure,↔ occludin [84]
IL-1, interleukin 1; TGF-β, transforming growth factor beta; HGF/SF, hepatocyte growth
factor/scatter factor; HB-EGF, heparin-binding-epidermal growth factor; PDGF, platelet
derived growth factor; ⁎, transepithelial resistance; #, small molecule ﬂux; HUVECs,
human umbilical vascular endothelial cells; Caco-2, human colonic adenocarcinoma;
UEC, uterine epithelial cells; T84, human colonic epithelial cells; Calu-3, human lung
epithelial cells; PAC, primary airway cells; MDCK, Madin–Darby canine kidney cells;
ERK, extracellular signal-regulated kinases; MAPK, mitogen-activated protein kinase;
SMAD, small mothers against decapentaplegic; PKC, protein kinase C; TJ, tight junction;
ZO-1, zonula occludins 1; NF-κB, nuclear factor-kappa B.occludin [14]. Interestingly, an IL-4-induced increase in intestinal
epithelial permeability has also been associated with increased
protein expression of claudin 2 [41,62]. Increases in claudin 2 alter
cell permeability, as exempliﬁed by claudin 2 overexpression in
epithelial cells, which lowers transepithelial resistance (TER) and
confers increased Na+ conductance [63–65]. In IL-6 knockout mice,
increased intestinal permeability to small molecules has been linked
to stability of ZO-1 in TJs [66]. Consistent with these ﬁndings, IL-6
treatment in-vitro also increases permeability across endothelial cells
and produces ZO-1 mislocalization, actin structure remodeling, and
increased actin contractility [67]. In many circumstances IL-10
opposes the inﬂuence of pro-inﬂammatory cytokines such as IFN-γ
on the barrier properties of the epithelium or endothelium [68,69].
Mazzon et al. have observed that IL-10 knockout mice, a model of
spontaneous colitis, have increased levels of pro-inﬂammatory
cytokines TNF-α, IL-1, and IL-6 [70]. IL-10 ablation also correlates
with mislocalization of ZO-1 and claudin 1 away from TJs and may
reﬂect the action of increased pro-inﬂammatory cytokines [70]. Direct
treatment of airway epithelial cells with IL-13 causes decreased TER
and enhanced manatol ﬂux and lower ZO-1 protein levels [14]. IL-13
mediated barrier dysfunction in T84 cells also correlates with
increased claudin 2 protein levels [41]. IL-13 and IL-4 act synergisti-
cally to stimulate the classical STAT6 pathway, although the involve-
ment of this pathway in TJ structure and function has not been directly
evaluated [71].
Many interleukins act as modulators of TJ components, control-
ling occludin, claudin, and ZO-1 protein levels. These in turn form TJs
with altered permeability characteristics. Alternatively, interleukins 2
and 10 act to antagonize the action of pro-inﬂammatory cytokines
on TJ permeability, although the mechanisms involved are poorly
understood.
6. Growth factors
Growth factors have a variety of effects on paracellular perme-
ability, either increasing or decreasing permeability, depending on the
cell environment (Table 2). Transforming growth factor beta (TGF-β)
is a multifunctional cytokine that has been shown to enhance
epithelial barrier properties in-vitro [72,73]. TGF-β binding to its cell
surface receptor TGFRβI/II promotes SMAD mediated signaling to the
nucleus. Recently, a SMAD independent pathway for TGF-β function
was linked to partitioning defective protein 6 (Par6) through SMURF1
ubiquitination and degradation of RhoA [74]. Par6, an evolutionarily
conserved regulator of cell polarity, is believed to act as a negative
regulator of TJ establishment, yet may support TJ integrity through
RhoA degradation [74,75]. Par6 is located at TJs and is in a constitutive
complex with atypical protein kinase C (aPKC), which together forms
a complex with Par3 and Cdc42 [76]. Cdc42, a small Rho family
GTPase, is thought to act together with Par6 as a GTP dependent
molecular switch for the activation of aPKC [77]. Interestingly, aPKC
activity is required for SMURF1 degradation of RhoA [78], presenting
the possibility of a counter-acting mechanism to proinﬂammatory
cytokines. Like many cytokines, TGF-β exhibits pleiotropic effects, as it
increases permeability in uterine epithelial cells [32]. This is
consistent with studies in rat hepatocytes, which show decreases in
claudin 1 and increases in claudin 2 protein expression following
exposure of cells to TGF-β [79]. TGF-β regulation of claudin 1 was
found to proceed by a SMAD-dependent mechanism [73]. This may
reﬂect multiple functions for TGF-β that are dependent on the
biological setting. Indeed, TGF-β treatment is a model for the study of
cell–cell contact disruption during epithelial-mesenchymal transition
(EMT). The factors that dictate which of these pathways predominate
after TGF treatment are unknown. Variable effects in cell barrier
function are also seen with Hepatocyte Growth Factor/Scatter Factor
(HGF/SF) treatment. An HGF-induced increased permeability is
observed in epithelial and endothelial cells, and correlates with a
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SF exposure decreases uterine epithelial cell monolayer permeability
[32]. HGF/SF is also used to study EMT and acts to internalize junction
proteins in a clathrin dependent mechanism in Madin–Darby canine
kidney cells (MDCK) [82]. Heparin binding epidermal growth factor
(HB-EGF) decreases permeability in MDCK cells, which is correlated
with suppression of claudin 2 protein levels [83]. Platelet-derived
growth factor (PDGF) increases small molecule ﬂux in MDCK cells
through modulation of TJ structure and displacement of occludin [84].
Although varied in their effects on barrier properties, growth factors
and cytokines act by similar mechanisms, including displacement or
down regulation of TJ protein components and regulation of RhoA.
Further studies will be needed to determine the signaling pathways
that mediate these effects.
7. Mechanisms of tight junction regulation by cytokines
Although cellular responses to cytokines show cell type speciﬁc,
pleiotropic, and time and dose-dependent effects, common mechan-
isms for TJ modulation emerge. These include cytokine induced actin
remodeling and changes in TJ structure. By and large, in-vitro cell
culture systems have shown that cytokines alter TJs independent of
apoptosis. Epithelial and endothelial barrier continuity, when dis-
rupted by cell apoptosis, leads to increases in tissue permeability.
Cytotoxic effects due to cytokines have been described in a variety of
cell lines and are dependent on the dose and duration of TNF-α and
IFN-γ exposure [85]. Yet under experimental conditions that increase
cell permeability, apoptosis was excluded as a mechanism in T84 cells
treated with TNF-α and IFN-γ [17,22,36,86]. For example, pharmaco-
logical inhibition of apoptosis fails to attenuate increases inmonolayer
permeability [46]. Therefore, cytokines are capable of directly
modifying TJ composition and structure through signaling pathways
independent of cell death.
7.1. Claudin/occludin turnover at the tight junction
A recent study by Zeissig et al. found aberrant expression of
claudin 2, 5 and 8 in Crohn's disease patients. Surprisingly, these
claudins were found to be increased in non-inﬂamed segments of the
intestine [87]. Similar changes in claudin expression were not found
in the same patients during periods of remission, suggesting that
cytokines induce TJ remodeling and changes in claudin expression
[88]. Indeed, recent studies in our laboratory demonstrated that
increased susceptibility to experimentally induced colitis in JAM-A
knockout animals correlated with increased expression of pore
forming claudins (10 and 15) prior to experimental injury [89].
Changes in the claudin compliment within TJs affects the size and
charge selectivity of the paracellular pathway as well as the structure
of the TJ stands. A review of recent data groups claudins into two
types, pore-forming claudins (2, 7, 10, 15, and 16) and sealing claudins
(1, 4, 5, 8, 11, 14 and 19) [90]. Most of these claudins remain to be
investigated and it is unclear by what mechanism claudin exchange
takes place after cytokine exposure. It is believed that claudins are
constitutively internalized and recycled in epithelial cells during
normal junction maintenance and homeostasis [91]. Changes in TJ
components could be due to increases in turnover rate at the expense
of integration. Paracellular pore characteristic may therefore be
altered through the exchange of transmembrane components, or by
increasing/decreasing the number of existing pores (Fig. 1.1). Indeed,
cell line speciﬁc paracellular permeability has recently been attrib-
uted to changes in the density and number of pores between cells
[92]. Therefore, both the number and the character of claudins
expressed in a cell after cytokine treatment have the potential to alter
paracellular barrier function.
Occludin and claudin protein function and stability can be
regulated by post-transcriptional modiﬁcation of C-terminal residues[93–95]. Phosphorylation in these domains has been shown to
increase protein internalization. For example, EphA2 phosphorylation
of the claudin 4 C-terminus disrupts the interaction of ZO-1 and
claudin 4 localization in the membrane [96]. Claudin C-terminal
cytoplasmic domains have PKC and Protein kinase A (PKA) phosphor-
ylation sites within the C-terminal cytoplasmic domain [90,97]. PKA-
dependent phosphorylation of the serine residue in position-2 of the K+
channel Kir 2.3 disrupts interaction with PSD-95 [98]. These modiﬁca-
tions may therefore increase protein turnover or disrupt interactions
with scaffolding proteins. Both are thought to disrupt TJ structure and
function. Interestingly, TNF-α induced permeability changes can be
ameliorated by the PKA inhibitor H-8, and cytokine effects can be
attenuated by PKC inhibitors [2, 99]. Cytokine-induced changes in TJ
permeability have previously been linked to alterations in tyrosine
kinases and PKC [67,99]. Indeed, IL-6 induced permeability increases
can be attenuated by pharmacological inhibition of PKC and with a PKC
pseudosubstrate [67].
Cytokine regulation of transmembrane protein transcription
would be a powerful mechanism for TJ remodeling. Recent studies
indicate that occludin downregulation by IL-1 is dependent on NF-κB
signaling [53]. NF-κB is a co-factor for transcription and a classic
mediator of inﬂammatory signals to the nucleus. NF-κB activation
within the ﬁrst hour of IL-1β treatment is vital for TER disruption [53].
Therefore, NF-κB activation occurs prior to permeability increases and
mediates the observed changes in occludin and claudin protein levels.
SMAD4, a mediator of TGF-β signaling, suppresses claudin 1 levels in
SW480 cells, although the link to cytokine signaling and claudin 1
expression is unclear [100].
7.2. Actin cytoskeletal contraction and endocytosis of tight
junction proteins
Wholesale disassembly of TJs is studied experimentally by
incubation of cells in low or calcium-free media (calcium switch),
which internalizes both adherens junctions and TJs. In low calcium
conditions, endothelial cell monolayers lose barrier function through
actin mediated internalization of E-cadherin [101]. Epithelial
cultures lose barrier properties after calcium reduction and this
has been shown to proceed via clathrin mediated membrane vesicle
endocytosis [102]. Interestingly, endocytosis in both calcium deple-
tion experiments and cytokine treatments lead to actin reorganiza-
tion and activation of myosin dependent contractility [103]. In this
model, peripheral actin ring structures contract in a non-muscle
myosin dependent manner, which coincides with internalization of
TJ structural proteins [103]. Cytochalasin D treatment increases
permeability in MDCK cells and inhibits TJ restructuring after
calcium depletion [104]. The same is true for Cytochalasin B,
indicating actin related processes are required for endocytosis as
well as junction reassembly [105]. Blebbistatin treatment, which
inhibits the myosin II motor, also attenuates loss of junction
complexes in the calcium switch model of junction disassembly
[103]. Enteropathogenic bacteria induce increases in epithelial
permeability in a manner similar to cytokine exposure, and requires
MLC phosphorylation [42,106]. These experimental systems are
models of junction disassembly and barrier dysfunction, and share
several features seen in cytokine treated cells. These include vesicle
endocytosis and contraction of acto-myosin based cytoskeletal
networks.
Cytokine mediated restructuring of TJs proceeds through a variety
of different signaling pathways to affect paracellular permeability. A
synthesis of current data with the aim of distilling common
mechanisms, is complicated by pleiotropic cytokine actions as well
as temporal and dose dependent variation in cell culture systems. For
example, endothelial cells in-vivo may be required to maintain
barrier function during exposure to chronic low-levels of systemic
cytokines during an inﬂammatory response, and therefore respond
869C.T. Capaldo, A. Nusrat / Biochimica et Biophysica Acta 1788 (2009) 864–871differentially to low cytokine levels in model cell culture systems.
Yet modulation of TJ properties by cytokines appears to proceed
through two distinct processes, the remodeling of TJs by selectively
removing or introducing TJ components (Fig. 1.1) or the wholesale
restructuring of TJ and actin networks (Fig. 1.1). Several lines of
evidence indicate that these processes may function simultaneously
or sequentially. Although it should be recognized that during in-vivo
inﬂammatory events the cytokine environment experienced by the
cell is quite complex and the processes of cytokine modulation of
TJs are unclear, our understanding of the molecular mechanisms
involved is expanding rapidly through the use of reductionistic cell
culture systems.
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